dr. van cutsem discusses regorafenib for the treatment of patients with chemorefractory mcrc
Published 8 years ago • 143 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
24:26
dr. van cutsem on regorafenib for patients with colorectal cancer
-
8:18
the optimal dosing strategy for regorafenib in mcrc
-
1:31
dr. eric van cutsem on regorafenib for metastatic colorectal cancer
-
4:53
debate: salvage therapy for mcrc? - tas-102 followed by regorafenib
-
5:31
practical advice for using regorafenib
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
32:56
colorectal cancer and immunotherapy with dr. van morris
-
58:01
2024 asco highlights
-
34:17
colorectal cancer breakout: biomarkers for effective treatment
-
1:04
exploring regorafenib and nivolumab as treatment for colorectal cancer
-
2:36
prognostic value of metastatic sites in patients with mcrc treated with regorafenib
-
2:25
targeted therapy for mcrc
-
1:49
dr. george demetri describes the mechanism of action of regorafenib in gist
-
0:42
dr. keedy on regorafenib for the treatment of gist
-
0:49
dr. bendell on remaining questions with regorafenib in hcc
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
3:18
a dose-escalation study of regorafenib in mcrc
-
7:35
use of regorafenib in refractory mcrc
-
9:06
debate: is there an optimal treatment for refractory colorectal cancer? - tas-102 or regorafenib
-
0:58
dr. kim reviews studies investigating regorafenib in mcrc
-
4:46
statement from eric van cutsem about the clinical significance of trifluridine/tipiracil